Toll Free: 1-888-928-9744
Published: Feb, 2014 | Pages:
46 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Pluristem Therapeutics Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Pluristem Therapeutics Inc. - Product Pipeline Review - 2014', provides an overview of the Pluristem Therapeutics Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Pluristem Therapeutics Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Pluristem Therapeutics Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Pluristem Therapeutics Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Pluristem Therapeutics Inc.'s pipeline products Reasons to buy - Evaluate Pluristem Therapeutics Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Pluristem Therapeutics Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Pluristem Therapeutics Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Pluristem Therapeutics Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pluristem Therapeutics Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Pluristem Therapeutics Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Pluristem Therapeutics Inc. Snapshot 5 Pluristem Therapeutics Inc. Overview 5 Key Information 5 Key Facts 5 Pluristem Therapeutics Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Pluristem Therapeutics Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pluristem Therapeutics Inc. - Pipeline Products Glance 13 Pluristem Therapeutics Inc. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Pluristem Therapeutics Inc. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Pluristem Therapeutics Inc. - Unknown Stage Pipeline Products 16 Unknown Products/Combination Treatment Modalities 16 Pluristem Therapeutics Inc. - Drug Profiles 17 PLX Cells for Peripheral Artery Disease 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 PLX-ORTHO 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 PLX-BMP 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 PLX Cells for Acute Myocardial Infarction 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 PLX Cells for Aplastic Bone Marrow 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 PLX Cells For GvHD 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 PLX Cells for Inflammatory Bowel Disease 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 PLX Cells for Ischemic Stroke 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 PLX Cells for Multiple Sclerosis 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 PLX Cells For Neuropathic And Inflammatory Pain 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 PLX Cells For Pre-Eclampsia 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 PLX-PAD for Pulmonary Fibrosis 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Pluristem Therapeutics Inc. - Pipeline Analysis 32 Pluristem Therapeutics Inc. - Pipeline Products by Route of Administration 32 Pluristem Therapeutics Inc. - Pipeline Products by Molecule Type 33 Pluristem Therapeutics Inc. - Recent Pipeline Updates 34 Pluristem Therapeutics Inc. - Dormant Projects 43 Pluristem Therapeutics Inc. - Locations And Subsidiaries 44 Head Office 44 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 46 Disclaimer 46
List of Tables Pluristem Therapeutics Inc., Key Information 5 Pluristem Therapeutics Inc., Key Facts 5 Pluristem Therapeutics Inc. - Pipeline by Indication, 2014 8 Pluristem Therapeutics Inc. - Pipeline by Stage of Development, 2014 9 Pluristem Therapeutics Inc. - Monotherapy Products in Pipeline, 2014 10 Pluristem Therapeutics Inc. - Partnered Products in Pipeline, 2014 11 Pluristem Therapeutics Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12 Pluristem Therapeutics Inc. - Phase II, 2014 13 Pluristem Therapeutics Inc. - Phase I, 2014 14 Pluristem Therapeutics Inc. - Preclinical, 2014 15 Pluristem Therapeutics Inc. - Unknown, 2014 16 Pluristem Therapeutics Inc. - Pipeline by Route of Administration, 2014 32 Pluristem Therapeutics Inc. - Pipeline by Molecule Type, 2014 33 Pluristem Therapeutics Inc. - Recent Pipeline Updates, 2014 34 Pluristem Therapeutics Inc. - Dormant Developmental Projects,2014 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.